CoreWeave is in the News Because of Nvidia Again: Do You Buy It?
CoreWeave sits at a crossroads where triple-digit revenue growth collides with a balance sheet that would make most CFOs sweat, and the latest Nvidia headlines just handed investors a decision they cannot afford to get wrong.
CoreWeave (NASDAQ:CRWV) at $83.35 warrants a closer look now rather than later as fresh NVIDIA-adjacent headlines reshape the setup. The stock has been a lightning rod for AI infrastructure sentiment, and it just got dragged lower again as the market digested fresh commentary about OpenAI’s spending ambitions and what that could funnel toward NVIDIA’s preferred cloud partners.
CoreWeave rents out NVIDIA GPU capacity at scale, and it sits in an unusual spot in the AI stack. NVIDIA is its largest supplier, an equity investor via a $2 billion Class A investment, and a strategic partner on a $6.3 billion collaboration to build 5+ GW of AI factories by 2030. That intimacy is why every NVIDIA product cycle, from Grace Blackwell to Vera Rubin, ends up moving CRWV shares (and it is also why the power, cooling, and networking names sitting behind those AI factories keep showing up in our free AI infrastructure report, here).
The stock is down 21.37% over the past month and 29.81% over the past year, even as the underlying business grew triple digits again.
Why the Sell-Off Looks Like an Opening
Q2 revenue landed at $2.6 billion, up 112% year over year, with adjusted EBITDA of $1.5 billion at a 59% margin. Revenue backlog stands at $104 billion, plus $25 billion+ in new customer commitments added in early Q3 2026. Management guided full-year revenue to $12.4 billion to $13.2 billion and a year-end run-rate of $18.5 billion to $19.5 billion.
Pricing is inflecting the right way. A roughly 25% increase across SKUs hit in July, and CEO Mike Intrator said new contracts carry contribution margins “5 to 10 percentage points above those added in recent quarters.” Being first to deploy Vera Rubin NVL72 gives CoreWeave the scarcest silicon in the market at a moment when demand is broadening from frontier labs into enterprise, defense, and industrial AI.
Why the Bears Are Not Wrong Either
The balance sheet is the pressure point. Q2 capex was $9.4 billion, free cash flow was negative $5.74 billion, and interest expense jumped to $640 million from $267 million a year earlier. Debt-to-equity sits at 8.94, and the company is guiding $35 billion to $39 billion of full-year capex. A securities fraud class action alleging concealed data center construction delays adds legal overhang, and Meta Platforms (NASDAQ:META | META Price Prediction) plus OpenAI dominate the backlog. Reddit sentiment during the recent slide was uniformly very bearish.
Case for Waiting a Quarter
Analysts have quietly walked estimates lower, with 11 downward EPS revisions for the September quarter against just three upward. Management promised adjusted operating margins reach low teens in Q4, and the Q3 print will tell investors whether the pricing hike is landing. Patient buyers can wait for that confirmation and for clarity on debt refinancing terms before scaling in.
What the Numbers Say About the Setup
Shares trade at $83.35 against an analyst target of $144.46, a meaningful gap to the current price if the Street is right, though targets are only one data point. Of 38 analysts tracked, the breakdown is 5 Strong Buy, 21 Buy, 10 Hold, 1 Sell, and 1 Strong Sell. Year to date CRWV is up 16.39% versus 10.59% for the S&P 500, but the one-year return of -29.81% trails the index’s 14.26% gain by a wide margin. Price-to-sales stands at 5.88 with EV/EBITDA at 23, reasonable for a business growing revenue 112% year over year.
Verdict: Weighing Weakness With Eyes Open
At $83.35, the risk-reward profile is worth examining closely. Here is why.
The path to price appreciation is mechanical. Q3 revenue guidance of $3.45 billion to $3.6 billion combined with July’s 25% pricing step-up should produce the margin inflection management has telegraphed. If Q4 adjusted operating margins hit the low-teens target, the stock re-rates. First-mover access to Vera Rubin economics remains difficult for peers to replicate quickly.
The current price bakes in real pain already. Shares are 45% off the 52-week high of $153.20, and Barron’s flagged that OpenAI’s expanding footprint could lift Oracle and CoreWeave from AI gloom. That is the setup for asymmetric upside when a preferred NVIDIA partner trades at a discount to its own trend.
What invalidates the thesis is a broken data center delivery schedule, a debt refinancing at punitive rates, or a customer concentration event with Meta or OpenAI. Watch construction timing and interest costs quarter by quarter. Buying an unprofitable, highly levered AI infrastructure builder is not for everyone, but at this price, with this backlog and this NVIDIA relationship, the risk-reward profile shifts materially for investors evaluating the name.
Contact [email protected] for any questions or corrections.
Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.
